Congresso da EAACI 2024: Inovação e Avanços no Tratamento da Alergia
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Durante o congresso serão apresentadas mais de 150 sessões científicas, centradas nos avanços da ciência ambiental, alergias alimentares, inovações em imunoterapia e alergias pediátricas, entre...
EAACI Congress 2024: Innovationen und Fortschritte in der Allergietherapie
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Im Rahmen des Kongresses werden über 150 wissenschaftliche Vorträge gehalten, die sich unter anderem mit Fortschritten in den Bereichen Umweltwissenschaft, Lebensmittelallergien, Innovationen in der...
EAACI Congress 2024：創新與過敏治療進展
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
大會期間將呈獻超過 150 場科學會議，重點關注環境科學、食物過敏、免疫療法創新和兒童過敏等方面的進展。精準醫療、AI、免疫療法和免疫調節劑將匯聚在此次最大型的過敏和免疫學大會上。大會將於 5 月 31 日至 6 月 3 日在西班牙華倫西亞舉行。 華倫西亞，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 歐洲過敏和臨床免疫學會 (European...
2024 年欧洲过敏与临床免疫学会大会：过敏治疗的创新和进步
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
大会期间将举行 150 多场科学会议，重点探讨环境科学、食物过敏、免疫疗法创新和儿科过敏等方面的进展。作为规模最大的过敏和免疫学盛会，本次大会将汇聚精准医学、人工智能、免疫疗法和免疫调节剂等前沿领域。大会将于 5 月 31 日至 6 月 3 日在西班牙巴伦西亚举行。 巴伦西亚，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 由来自 125 个国家的...
Medigene AG reports Financial Results and Business Update for Q1 2024
26 avr. 2024 03h00 HE
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
25 avr. 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24 avr. 2024 07h00 HE
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
17 avr. 2024 06h00 HE
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
08 avr. 2024 02h00 HE
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its iM-TCR Technology
04 avr. 2024 05h00 HE
|
Medigene AG
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...